Review anchor
Voltage-dependent N-type calcium channel subunit alpha-1B
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Voltage-dependent N-type calcium channel subunit alpha-1B
CHEMBL4478
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Voltage-dependent N-type calcium channel subunit alpha-1B as ChEMBL target CHEMBL4478, mapped to UniProt Q00975. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4478
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q00975
Voltage-dependent N-type calcium channel subunit alpha-1B
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Voltage-dependent N-type calcium channel subunit alpha-1B matters
Voltage-dependent N-type calcium channel subunit alpha-1B is reviewed as Voltage-dependent N-type calcium channel subunit alpha-1B (UniProt Q00975); Voltage-dependent N-type calcium channel subunit alpha-1B shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 13 approved drugs, 801 compounds, and 110 assays, with lead potency reaching pChEMBL 9.0.
Protein context
Voltage-dependent N-type calcium channel subunit alpha-1B
Voltage-dependent N-type calcium channel subunit alpha-1B Sequence length is 2339 aa.
Review this target as Voltage-dependent N-type calcium channel subunit alpha-1B, mapped to UniProt Q00975. Sequence length is 2339 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q00975
Protein
Disease context
pain
Voltage-dependent N-type calcium channel subunit alpha-1B shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include RALFINAMIDE, ZICONOTIDE, ZICONOTIDE ACETATE.
Start review with pain because it currently carries approved-linked support. Linked drugs include RALFINAMIDE, ZICONOTIDE, ZICONOTIDE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
3 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 13 approved drugs, 801 compounds, and 110 assays for this target. The dominant activity type is IC50. CHEMBL4279774 is the current potency anchor at pChEMBL 9.0.
Use CHEMBL4279774 as the tractability anchor when discussing potency (pChEMBL 9.0).
Activity source · ChEMBL 36 via Core Engine
13 approved
pChEMBL 9.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Voltage-dependent N-type calcium channel subunit alpha-1B matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q00975, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why pain is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
801
Total Compounds
110
Total Assays
13
Approved Drugs
IC50: 774.0, KI: 11.0, EC50: 37.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4279774
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL4288564
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL4292697
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL4290426
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL4282095
|
8.7 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ZICONOTIDE
CHEMBL4594214
|
2004 |
|
|
MIBEFRADIL
CHEMBL45816
|
1997 |
Source Header